Additionally, a study using artificial intelligence to predict collateral lethal metabolic pathways, revealed the targeting of MTHFD2 as a vulnerability for ovarian cancers lacking ubiquinol-cytochrome c reductase, complex III subunit XI (UQCR11)147. This evidence concerns the gene UQCR11 and ovarian carcinoma.